Dapagliflozin: Pivotal agent in combination therapies for risk reduction in T2DM
04 Sep 2026
[ Combination therapies in Type 2 DM ]
Diabetes care and management have continuously evolved over the years.1-4 Current guidelines recommend combination therapy for initial treatment in adults with type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 inhibitors such as dapagliflozin have been in the forefront of this recommendation for adults with T2DM who have heart failure.4 Given the various medications available for T2DM, combination therapies must be tailored depending on each patient's co-morbidities. To learn further about different combination therapies for T2DM, access the infographic below.
To learn further about different combination therapies for T2DM, access the infographic below.
Diabetes care and management have continuously evolved over the years.1-4 Current guidelines recommend combination therapy for initial treatment in adults with type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 inhibitors such as dapagliflozin have been in the forefront of this recommendation for adults with T2DM who have heart failure.4 Given the various medications available for T2DM, combination therapies must be tailored depending on each patient's co-morbidities. To learn further about different combination therapies for T2DM, access the infographic below.
To learn further about different combination therapies for T2DM, access the infographic below.
Resources
Dapagliflozin: Pivotal agent in combination therapies for risk reduction in T2DM